23ME-00610 targets CD200R1, an important regulator of T cells and myeloid cells CD200R1 was identified as a promising immuno-oncology target through 23andMe’s proprietary genetic and health survey database Company will host a virtual R&D Day event on January 18, 2022 SUNNYVALE, Calif., Jan.